We are also developing a proprietary protein pathway database as a drug discovery and development tool for the pharmaceutical and biotechnology industries. We are extending our cancer pipeline by exploiting PSMA, which we exclusively licensed from Memorial Sloan-Kettering Cancer Center. PSMA is a unique antigen highly expressed in prostate cancer cells and in the neovasculature of a variety of other solid tumors, including breast, lung and colon. We also plan to apply our PSMA technology, including therapeutics and in vitro diagnostics, toward other types of cancer based upon our experience in prostate cancer. Inc. Proteomics Proteomics is the study of the expression and interaction of proteins.
Genomics is the study and identification of an organism's genetic makeup.
While genomics provides important information regarding genetic makeup, it does not directly provide information regarding protein functions or protein interactions. However, genomics data can prove useful in proteomics research as a source of obtaining complete protein sequences of ligands the Company has identified. Public availability of this genomic information allows for effective integration in the Company's database of public and proprietary information. The Company recognized in its past research that the key to understanding or developing the means to intervene in diseases was primarily based on understanding protein interactions rather than only through the use or study of genomics. The Company undertook this approach on its own initiative and with its own funds.